Literature DB >> 6403475

Enhancement of in vitro and in vivo antitumor activity by cord factor (6-6'-dimycolate of trehalose) administered suspended in saline.

S Orbach-Arbouys, J P Tenu, J F Petit.   

Abstract

The antitumor activity of trehalose-6,6'-dimycolate (TDM) dispersed in saline was studied in vitro and in vivo. In vitro, macrophages from TDM-treated mice entirely abolish, even at a 1.25:1 effector/target cell ratio, the (3H)TdR incorporation of P815 mastocytoma cells to the culture in which they were added. In vivo, the number of P815 cells harvested 10 days after their injection into TDM-treated mice was reduced by a factor higher than 50. The slopes of the radiolabel elimination of TDM-treated mice injected with 10(7) 125I-UdR-labelled L1210 leukemic cells were greater than those of untreated controls. The interest of such a compound which seems to be one of the active structures responsible for the antitumor activity of BCG is its efficiency when administered dispersed in saline.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403475     DOI: 10.1159/000233364

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  6 in total

1.  Trehalose 6,6'-dimycolate (Cord factor) enhances neovascularization through vascular endothelial growth factor production by neutrophils and macrophages.

Authors:  I Sakaguchi; N Ikeda; M Nakayama; Y Kato; I Yano; K Kaneda
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Interleukin-12 synthesis is a required step in trehalose dimycolate-induced activation of mouse peritoneal macrophages.

Authors:  I P Oswald; C M Dozois; J F Petit; G Lemaire
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

3.  Vaccination of rabbits against Entamoeba histolytica with aqueous suspensions of trehalose-dimycolate as the adjuvant.

Authors:  A Sharma; A Haq; S Ahmad; E Lederer
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

4.  Activation of rat alveolar macrophages and protection against i.v. injected tumor cells by intratracheal administration of trehalose dimycolate.

Authors:  D Nolibe; R Masse; J P Tenu; M Lepoivre; J F Petit
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Growth inhibition of tumour cells by a liposome-encapsulated, mycolic acid-containing glycolipid, trehalose 2,3,6'-trimycolate.

Authors:  Y Ohtsubo; M Furukawa; T Imagawa; N Sugimoto; M Ikutoh; S Nakatsugi; Y Katoh; S Shinka; Y Dohi
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

6.  Parallel antitumor, granuloma-forming and tumor-necrosis-factor-priming activities of mycoloyl glycolipids from Nocardia rubra that differ in carbohydrate moiety: structure-activity relationships.

Authors:  Y Natsuhara; S Oka; K Kaneda; Y Kato; I Yano
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.